Tradestie Institutional Equity Comparison Engine
BHVN vs RAPT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
RAPT Overall Edge
RAPT Captures Institutional Edge (1โ1 Pillars ยท 4โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to RAPT Therapeutics, Inc. Common Stock (RAPT) driven by superior Momentum & Technical while BHVN counters with relative strength in Options & Structure. Fundamentally, BHVN trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus RAPT at N/M Forward P/E and 0.0% operating margin (-100.0% YoY). In options structure, BHVN sits in CONSOLIDATION (18th %ile IV; Dealer Gamma Walls on Pro) against RAPT sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
BHVN N/M vs RAPT N/M Fwd P/E
Growth & Margin Winner
Tie
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs -100.0%
Momentum & Technical Winner
RAPT
1Y +72.6% vs +480.2% ยท 52W Pos 59% vs 100%
Options & Structure Winner
BHVN
CONSOLIDATION (18th %ile IV) vs UNCLASSIFIED (<1st %ile IV)
BHVN
NYSE
Biohaven Ltd.
Pharmaceutical Preparations
$13.95
+0.9% 1D
Market Cap
$2.1B
1M Return
+29.36%
1Y Return
+72.59%
Forward P/E
N/M
Unified AI Score
42.1 / 100
HOLD
Tech 15.0
Fund 42.0
Flow 68.0
Mom 50.0
RAPT
NASDAQ
RAPT Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$58.02
+0.07% 1D
Market Cap
$1.7B
1M Return
+0.68%
1Y Return
+480.2%
Forward P/E
N/M
Unified AI Score
52.4 / 100
HOLD
Tech 40.0
Fund 46.0
Flow 61.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
BHVN +72.59%
RAPT +480.2%
Spread: +59.66 pp (RAPT Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
BHVN TTM Op. Margin: 0.0%
RAPT TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on BHVN vs RAPT. Trailing 12-month operating profitability (BHVN 0.0% vs RAPT 0.0%) and valuation multiples (BHVN N/M vs RAPT N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | BHVN | RAPT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $2.1B | $1.7B | Larger Scale | BHVN |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | -100.0% | Higher Growth | BHVN |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -799.5% | -85.4% | Higher ROE | RAPT |
| 52-Week Range Position Momentum | 59% ($8โ$18) | 100% ($1โ$58) | Stronger Trend | RAPT |
| Beta / 30D Volatility Risk Regime | 1.40ฮฒ ยท 111% Vol | -0.02ฮฒ ยท 2% Vol | Lower Realized Risk | RAPT |
| Unified Institutional Score Composite Signal | 42.1 / 100 (HOLD) | 52.4 / 100 (HOLD) | Higher Composite | RAPT |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full BHVN vs RAPT Buy Guide
BHVN
CONSOLIDATION
91d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
18th %ile
IV Regime
Compressed (<25th %ile)
RAPT
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
<1st %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither BHVN nor RAPT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.